[Buccotemporal space and other fascial spaces of the deep lateral face region].

W. Zenker

Zeitschrift für Anatomie und Entwicklungsgeschichte

Abstract:

What problem does this paper attempt to address?

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives

Giulia Santo,Gianpaolo Di Santo,Irene Virgolini

DOI: https://doi.org/10.1053/j.semnuclmed.2024.02.002

IF: 4.802

2024-03-17

Seminars in Nuclear Medicine

Abstract:Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy for patients with neuroendocrine tumors (NET). First performed already more than 30 years ago, PRRT was incorporated only in recent years into the major oncology guidelines, based on its proven efficacy and safety in clinical trials. Following the phase 3 NETTER-1 trial, which led to the final registration of the radiopharmaceutical Luthatera® for G1/G2 NET patients in 2017, the long-term results of the phase 3 NETTER-2 trial may pave the way for a new treatment option also for advanced G2/G3 patients as first-line therapy. The growing knowledge about the synergistic effect of combined therapies could also allow alternative (re)treatment options for NET patients, in order to create a tailored treatment strategy. The evolving thera(g)nostic concept could be applied for the identification of patients who might benefit from different image-guided treatment strategies. In this scenario, the use of dual tracer PET/CT in NET patients, using both [ 18 F]F-FDG/[ 68 Ga]Ga-DOTA-somatostatin analog (SSA) for diagnosis and follow-up, is under discussion and could also result in a powerful prognostic tool. In addition, alternative strategies based on different metabolic pathways, radioisotopes, or combinations of different medical approaches could be applied. A number of different promising "doors" could thus open in the near future for the treatment of NET patients - and the "key" will be thera(g)nostic!

radiology, nuclear medicine & medical imaging
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Nadine Mallak,Burcak Yilmaz,Catherine Meyer,Celeste Winters,Anna Mench,Abhinav Jha,Vikas Prasad,Erik Mittra

DOI: https://doi.org/10.1016/j.currproblcancer.2024.101129

2024-09-03

Abstract:Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Elettra Merola,Chiara Maria Grana

DOI: https://doi.org/10.3390/cancers15112975

2023-05-30

Abstract:Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has emerged as a crucial strategy for treating advanced, unresectable neuroendocrine tumors by administering radiolabeled somatostatin analogs intravenously to target SSTRs. This article will focus on the multidisciplinary theranostic approach, treatment effectiveness (such as response rates and symptom relief), patient outcomes, and toxicity profile of PRRT for NEN patients. We will review the most significant studies, such as the phase III NETTER-1 trial, and discuss promising new radiopharmaceuticals, including alpha-emitting radionuclide-labeled somatostatin analogs and SSTR antagonists.
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023

Gianpaolo di Santo,Giulia Santo,Anna Sviridenko,Irene Virgolini

DOI: https://doi.org/10.7150/thno.91268

IF: 11.6

2024-01-01

Theranostics

Abstract:A growing body of literature reports on the combined use of peptide receptor radionuclide therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with perhaps increased safety issues. Combination treatments to enhance PRRT outcome are based on improved tumour perfusion, upregulation of somatostatin receptors (SSTR), radiosensitization with DNA damaging agents or targeted therapies. Several Phase 1 or 2 trials are currently recruiting patients in combined regimens. The combination of PRRT with cytotoxic chemotherapy, capecitabine and temozolomide (CAPTEM), seems to become clinically useful especially in pancreatic neuroendocrine tumours (pNETs) with acceptable safety profile. Neoadjuvant PRRT prior to surgery, PRRT combinations of intravenous and intraarterial routes of application, combinations of PRRT with differently radiolabelled (alpha, beta, Auger) SSTR-targeting agonists and antagonists, inhibitors of immune checkpoints (ICIs), poly (ADP-ribose) polymerase-1 (PARP1i), tyrosine kinase (TKI), DNA-dependent protein kinase, ribonucleotide reductase or DNA methyltransferase (DMNT) are tested in currently ongoing clinical trials. The combination with [<sup>131</sup>I]I-MIBG in rare NETs (such as paraganglioma, pheochromocytoma) and new non-SSTR-targeting radioligands are used in the personalization process of treatment. The present review will provide an overview of the current status of ongoing PRRT combination treatments.

medicine, research & experimental
Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

Baptiste Camus,Anne-Ségolène Cottereau,Lola-Jade Palmieri,Solène Dermine,Florence Tenenbaum,Catherine Brezault,Romain Coriat

DOI: https://doi.org/10.3390/jcm10061267

2021-03-18

Abstract:Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared177Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.
Theranostics in Neuroendocrine Tumors

Nadine Mallak,Sophia R O'Brien,Daniel A Pryma,Erik Mittra

DOI: https://doi.org/10.1097/PPO.0000000000000723

Abstract:Neuroendocrine tumors (NETs) are rare tumors that develop from cells of the neuroendocrine system and can originate in multiple organs and tissues such as the bowels, pancreas, adrenal glands, ganglia, thyroid, and lungs. This review will focus on gastroenteropancreatic NETs (more commonly called NETs) characterized by frequent somatostatin receptor (SSTR) overexpression and pheochromocytomas/paragangliomas (PPGLs), which typically overexpress norepinephrine transporter. Advancements in SSTR-targeted imaging and treatment have revolutionized the management of patients with NETs. This comprehensive review delves into the current practice, discussing the use of the various Food and Drug Administration-approved SSTR-agonist positron emission tomography tracers and the predictive imaging biomarkers, and elaborating on 177Lu-DOTATATE peptide receptor radionuclide therapy including the evolving areas of posttherapy imaging practices and peptide receptor radionuclide therapy retreatment. SSTR-targeted imaging and therapy can also be used in patients with PPGL; however, this patient population has demonstrated the best outcomes from norepinephrine transporter-targeted therapy with 131I-metaiodobenzylguanidine. Metaiodobenzylguanidine theranostics for PPGL will be discussed, noting that in 2024 it became commercially unavailable in the United States. Therefore, the use and reported success of SSTR theranostics for PPGL will also be explored.
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

Philip E. Harris,Konstantin Zhernosekov

DOI: https://doi.org/10.3389/fendo.2022.941832

IF: 6.055

2022-11-01

Frontiers in Endocrinology

Abstract:Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation carrier-added Lu-177. PRRT has recently been developed for the treatment of neuroendocrine tumors (NETs). The majority of pancreatic and gastroenteric NETs (GEP-NETs) express the somatostatin receptors (SSTRs) 2 and 5. These receptors can be specifically targeted with a somatostatin peptide analogue (DOTATOC/DOTATATE) which can be chelated to a positron emission tomography (PET) emitting radioisotope such as Ga-68 for imaging or to a β-emitting radioisotope Lu-177 for therapy. A key advantage of this approach is that the receptor expression can be demonstrated by PET imaging before the patient is treated. Clinical studies in G1 and G2 GEP-NETS have demonstrated that PRRT is extremely effective in terms of progression free survival (PFS), symptom control and quality of life, with a well-established safety profile. A beneficial effect on outcome survival awaits to be confirmed. The first commercially available product Lu-177-DOTATATE was approved following the NETTER-1 trial in G1 and G2 GE-NETS. Lu-177-DOTATATE 7,4 GBq every 8 weeks for 4 cycles, together with octreotide LAR 30 mg monthly, demonstrated a median PFS of 28,4 months compared to 8,5 months for octreotide LAR 60 mg monthly. A second pivotal study COMPETE is currently in progress, comparing no carrier-added (n.c.a.) Lu-177-DOTATOC to the m-TOR inhibitor Everolimus in both GE-NETs and PNETs. Two studies, NETTER-2 and COMPOSE are currently underway in patients with high grade G2 and G3 NETs. Novel SSTR antagonists are being developed as next generation targeting molecules for SSTR2-expressing tumors. Antagonists have a higher tumor binding to receptors than agonists, opening up the potential indications for SSTR2 targeting to tumors which have a relatively lower expression of SSTR2 compared to NET such as small cell lung cancer, hepatocellular carcinoma and breast cancer. In addition to Lu-177, radioisotopes with different radiation properties such as Tb-161 and the α-emitter Ac-225 are being developed which have the potential to improve treatment efficacy across the range of G1 to G3 NETs.

endocrinology & metabolism
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

Morticia N. Becx,Noémie S. Minczeles,Tessa Brabander,Wouter W. de de Herder,Julie Nonnekens,Johannes Hofland

DOI: https://doi.org/10.3390/cancers14235792

2022-11-25

Cancers

Abstract:Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT.

oncology
Selective neuroinhibitory effects of taurine in slices of rat main olfactory bulb

O. Belluzzi,M. Puopolo,M. Benedusi,I. Kratskin

DOI: https://doi.org/10.1016/j.neuroscience.2003.12.032

IF: 3.708

2004-12-31

Neuroscience

Abstract:
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management

Wolfgang Roll,Matthias Weckesser,Robert Seifert,Lisa Bodei,Kambiz Rahbar

DOI: https://doi.org/10.1007/s00259-021-05359-3

2021-04-26

Abstract:Abstract Purpose The aim of this narrative review is to give an overview on current and emerging imaging methods and liquid biopsy for prediction and evaluation of response to PRRT. Current limitations and new perspectives, including artificial intelligence, are discussed. Methods A literature review of PubMed/Medline was performed with representative keywords. The search included articles published online through August 31, 2020. All searches were restricted to English language manuscripts. Results Peptide radio receptor therapy (PRRT) is a prospectively evaluated and approved therapy option in neuroendocrine tumors (NETs). Different ligands targeting the somatostatin receptor (SSTR) are used as theranostic pairs for imaging NET and for PRRT. Response assessment in prospective trials often relies on the morphological RECIST 1.1 criteria, based on lesion size in CT or MRI. The role of SSTR-PET and quantitative uptake parameters and volumetric data is still not defined. Monoanalyte tumor marker chromogranin A has a limited value for response assessment after PRRT. New emerging liquid biopsy techniques are offering prediction of response to PRRT and prognostic value. Conclusions New response criteria for NET patients undergoing PRRT will comprise multiparametric hybrid imaging and blood-based multianalyte markers. This represents tumor biology and heterogeneity.
[Correlation between clinical status and psychological variables in juvenile diabetics (author's transl)].

H. Steinhausen,S. Börner

1979-03-01

Abstract:Correlations between clinical status and psychological variables in 56 juvenile diabetics were studied. Intelligence was only partly associated with clinical status. Among personality variables extraversion proved to be correlated with insufficient clinical control. This result is significant, both from a theoretical and from a practical point of view. There were no correlations of parental personality and clinical control.
Peptide receptor radionuclide therapy in patients with advanced pancreatic neuroendocrine tumors

Chen Yonghui,Jia Bing,Li Fang,Wang Fan,Lin Yansong

DOI: https://doi.org/10.1053/j.seminoncol.2018.08.004

IF: 5.385

2018-01-01

Seminars in Oncology

Abstract:177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is now approved for patients with advanced gastroenteropancreatic neuroendocrine tumors (NET), and it is therefore important to understand the efficacy and safety of PRRT in this patient population. PRRT efficacy and safety outcomes have frequently been summarized for patient populations with gastroenteropancreatic NET, but not specifically in patients with pancreatic NET (panNET). The pivotal phase 3 trial of 177Lu-DOTATATE PRRT in NET was restricted to patients with a midgut primary site. No phase 3 trial data on PRRT treatment outcomes are currently available for the panNET patient population. This review presents the available evidence for panNET treatment outcomes with PRRT and demonstrates that the available data favor PRRT as a modality for this NET primary site. However, several other therapies for advanced panNET are currently available, and the sequencing and combination of PRRT with these other therapies is set to become the big challenge for the future of panNET management. Patient, tumor, and logistical factors (tumor burden, expression of somatostatin receptors, availability of PRRT, patient preferences, and concerns over long-term toxicity) need to be taken into consideration when selecting therapy.
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies

Nils Florian Trautwein,Clemens Hinterleitner,Lena Sophie Kiefer,Stephan Singer,Sven Mattern,Johannes Schwenck,Gerald Reischl,Bence Sipos,Ulrich M. Lauer,Helmut Dittmann,Lars Zender,Christian la Fougère,Martina Hinterleitner

DOI: https://doi.org/10.1097/rlu.0000000000005006

IF: 10.6

2024-01-23

Clinical Nuclear Medicine

Abstract:Abstract Aim/Introduction Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor–positive NET with higher proliferation rates, a value and potential therapeutic benefit of PRRT as part of multimodal treatment approaches and potentially with addition of radiosensitizing agents has not yet been established. Patients and Methods In this study, 20 patients with histologically confirmed gastroenteropancreatic (GEP) NET with proliferation rates (Ki67) between 15% and 55% were treated either with PRRT only (n = 10) or with a combination therapy (n = 10) comprising PRRT and capecitabine/temozolomide (CAP/TEM) for at least 2 consecutive cycles. Results Disease control rate in patients treated with PRRT alone was 60% (40% stable disease and 20% partial response). Strikingly, in patients treated with PRRT in combination with radiosensitization (CAP/TEM), the disease control rate was 90% (20% stable disease and 70% partial response). The median progression-free survival in the PRRT only group was 12 months, whereas the median progression-free survival in the PRRT + CAP/TEM group was 26 months and has not been yet reached for all patients in the group during the observation period. The median disease-specific survival for patients with PRRT alone was 51 months, whereas this end point was not yet reached in the PRRT + CAP/TEM group. Moreover, the PRRT + CAP/TEM group showed a significantly higher reduction of SSTR-PET–based metabolic tumor volume and chromogranin A levels compared with the PRRT only group. Importantly, adverse events of all grades did not differ between both groups. Conclusions PRRT + CAP/TEM represents a highly promising and well-tolerated therapeutic regimen for patients experiencing somatostatin receptor–positive NET with higher (Ki67 ≥ 15%) proliferation rate. Prospective randomized clinical trials are warranted.

radiology, nuclear medicine & medical imaging
Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Ling Wang,Kun Tang,Qi Zhang,Huanbin Li,Zhengwei Wen,Hongzheng Zhang,Hong Zhang

DOI: https://doi.org/10.1155/2013/102819

2013-01-01

BioMed Research International

Abstract:Neuroendocrine tumors (NETs) are tumors originated from neuroendocrine cells in the body. The localization and the detection of the extent of NETs are important for diagnosis and treatment, which should be individualized according to the tumor type, burden, and symptoms. Molecular imaging of NETs with high sensitivity and specificity is achieved by nuclear medicine method using single photon-emitting and positron-emitting radiopharmaceuticals. Somatostatin receptor imaging (SRI) using SPECT or PET as a whole-body imaging technique has become a crucial part of the management of NETs. The radiotherapy with somatostatin analogues labeled with therapeutic beta emitters, such as lutetium-177 or yttrium-90, has been proved to be an option of therapy for patients with unresectable and metastasized NETs. Molecular imaging can deliver an important message to improve the outcome for patients with NETs by earlier diagnosis, better choice of the therapeutic method, and evaluation of the therapeutic response.
Ascorbic acid-2-sulfate of the brine shrimp, Artemia salina.

A. Bond,B. W. McClelland,J. Einstein,F. Finamore

DOI: https://doi.org/10.1016/0003-9861(72)90438-9

IF: 4.114

1972-11-01

Archives of Biochemistry and Biophysics

Abstract:
Thalamic Deep Brain Stimulation for Writer's Cramp.

C. Cho,H. Park,K. Lee,H. Rha

DOI: https://doi.org/10.3340/jkns.2009.46.1.52

2009-07-01

Journal of Korean Neurosurgical Society

Abstract:Writer's cramp is a type of idiopathic focal hand dystonia characterized by muscle cramps that accompany execution of the writing task specifically. There has been renewed interest in neurosurgical procedures for the treatment of dystonia over the past several years. In particular, deep brain stimulation (DBS) has received increasing attention as a therapeutic option for patients with dystonia. However, to date, limited reporters made investigations into DBS in relation to the Writer's cramp. In this case, unilateral Ventro-oralis complex (Vo) DBS resulted in a major improvement in patient's focal dystonic movement disorders. Her post-operative Burke-Fahn-Marsden Dystonia Rating (BFMDR) scale demonstrated 1 compared with pre-operative BFMDR scale 4. We conclude that thalamic Vo complex DBS may be an important neurosurgical therapeutic option for Writer's cramp.
Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms

Najeff Waseem,Carina Mari Aparici,Pamela L Kunz

DOI: https://doi.org/10.2967/jnumed.118.217851

Abstract:The diagnosis and subsequent therapy of neuroendocrine neoplasms (NENs) have long relied on somatostatin receptor (SSTR) expression. The field of theranostics now uses newer SSTR-based PET imaging with 68Ga-DOTATATE or 68Ga-DOTATOC as a prerequisite for the administration of peptide receptor radionuclide therapy (PRRT). In the United States, Food and Drug Administration approval of 177Lu-DOTATATE, a form of PRRT, in 2018 for use in gastroenteropancreatic NENs was obtained on the basis of prolonged progression-free survival versus high-dose octreotide long-acting release in a phase III clinical trial of well-differentiated midgut NENs. Well-differentiated grade 1 and grade 2 NENs have a low proliferation index (Ki-67 < 20%) and longer overall survival (>10 y), whereas higher-grade (grade 3 [G3]) NENs have a high Ki-67 (>20%) and shorter overall survival (<1 y). Here, we present a review on the role of SSTR-based imaging and PRRT in G3 NENs, including a discussion of well-differentiated G3 NENs, the newest histologic classification. Some studies suggest that G3 NENs are less likely to be positive on SSTR-based imaging (but more likely on 18F-FDG PET) than are well-differentiated NENs, but these data are limited. We found only 13 studies mentioning the use of PRRT in G3 NENs and a total of only 151 patients across these studies in whom radiologic response was measured. Of these 151 patients, 99 (66%) demonstrated at least stable disease or a partial response, indicating that some G3 NENs can be responsive to PRRT. We suggest that patients with G3 NENs should receive both 18F-FDG PET and SSTR-based imaging to aid in both diagnosis and treatment selection, as positivity on SSTR-based imaging helps with patient identification for PRRT and discordance may suggest important clues to tumor biology and prognosis. However, prospective studies are needed to fully understand the role of PRRT in G3 NENs, especially in well- versus poorly differentiated G3 disease.
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Mengqi Shi,Vivianne Jakobsson,Lukas Greifenstein,Pek-Lan Khong,Xiaoyuan Chen,Richard P Baum,Jingjing Zhang

DOI: https://doi.org/10.3389/fmed.2022.1034315

2022-12-07

Abstract:Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer cells with high precision. Unlike conventional external beam radiotherapy, PRRT utilizes primarily β or α radiation derived from nuclear decay, which causes damage to cancer cells in the immediate proximity by irreversible direct or indirect ionization of the cells' DNA, which induces apoptosis. In addition, to avoid damage to surrounding normal cells, PRRT privileges the use of radionuclides that have little penetrating and more energetic (and thus more ionizing) radiations. To date, the most frequently radioisotopes are β- emitters, particularly Yttrium-90 (90Y) and Lutetium-177 (177Lu), labeled SSTR agonists. Current development of SSTR-targeting is triggering the shift from using SSTR agonists to antagonists for PRRT. Furthermore, targeted α-particle therapy (TAT), has attracted special attention for the treatment of tumors and offers an improved therapeutic option for patients resistant to conventional treatments or even beta-irradiation treatment. Due to its short range and high linear energy transfer (LET), α-particles significantly damage the targeted cancer cells while causing minimal cytotoxicity toward surrounding normal tissue. Actinium-225 (225Ac) has been developed into potent targeting drug constructs including somatostatin-receptor-based radiopharmaceuticals and is in early clinical use against multiple neuroendocrine tumor types. In this article, we give a review of preclinical and clinical applications of 225Ac-PRRT in NETs, discuss the strengths and challenges of 225Ac complexes being used in PRRT; and envision the prospect of 225Ac-PRRT as a future alternative in the treatment of NETs.
Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource Environment

Mohammadreza Kalantarhormozi,Samaneh Hassanzadeh,Seyed Javad Rekabpour,Mohammad Reza Ravanbod,Esmail Jafari,AbdulLatif Amini,Habibollah Dadgar,Mehdi Mahmoudppour,Iraj Nabipour,Narges Jokar,Majid Assadi

DOI: https://doi.org/10.21203/rs.3.rs-111380/v1

2020-11-20

Abstract:Abstract BackgroundWe decided to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177-DOTATATE in patients with neuroendocrine tumors (NETs).MethodsSixteen patients with pathologically verified NETs including eight females and eight males were enrolled in this study. Before PRRT for evaluation of somatostatin receptor expressing, the patients underwent 68Ga-DOTATATE PET-CT or 99mTc-octreotide scintigraphy. The treatment response was assessed according to the response evaluation criteria in solid tumors (RECIST) which was classified into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). In addition, for evaluation of toxicity, monthly blood analysis was performed including hematology, renal function (creatinine), liver status. The Eastern Cooperative Oncology Group (ECOG) status performance was applied for estimating the patients’ general condition including 0 (fully active) to 5 (dead). In addition, overall survival (OS) was calculated as the time interval between start of PRRT to death from any reason.ResultsSixteen patients including eight females and eight males with median age of 60.5 years old with range of 24-74 were enrolled in this study. The patients underwent PRRT with median cycles of 3.5 with range of 1-7 and median dose of 20.35 with range of 7.4 to 49.95 GBq. At the end of data collection, 11/16 patients had PR, 2/16 showed CR, 1/16 showed SD and 2/16 showed PD according to the RECIST. 3 patients were expired during and after the PRRT period time. Before PRRT, the medians of ECOG and KPS were 1.5 and 75 which after treatment were, significantly, improved to 1 and 80, respectively (p<0.05). According to the Kaplan-Meier test, the median of OS was obtained 23 months (95%CI:7.90-38.09). According to the CTCAE, 3 patients showed grade I and 3 other showed grade II leucopenia. Furthermore, 3 and 7 patients had grade II and grade I anemia, respectively.ConclusionIt can be concluded that, since PRRT with 177Lu-DOTATATE in NETs has favorable response rate, few adverse effects and leads to improvement in QOL, it can be used as an effective therapeutic option specially in nonoperative, metastatic and progressive NETs.
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Paul M. D. Gape,Michael K. Schultz,Graeme J. Stasiuk,Samantha Y. A. Terry

DOI: https://doi.org/10.3390/ph17030334

IF: 4.6

2024-03-05

Pharmaceuticals

Abstract:This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs). The primary focus is on the transition from β-emitting radiopharmaceuticals to α-emitting agents in PRRT, offering a critical analysis of the radiobiological basis, clinical applications, and ongoing developments in Targeted Alpha Therapy (TAT). Through an extensive literature review, the article delves into the mechanisms and effectiveness of PRRT in targeting somatostatin subtype 2 receptors, highlighting both its successes and limitations. The discussion extends to the emerging paradigm of TAT, underlining its higher potency and specificity with α-particle emissions, which promise enhanced therapeutic efficacy and reduced toxicity. The review critically evaluates preclinical and clinical data, emphasizing the need for standardised dosimetry and a deeper understanding of the dose-response relationship in TAT. The review concludes by underscoring the significant potential of TAT in treating SSTR2-overexpressing cancers, especially in patients refractory to β-PRRT, while also acknowledging the current challenges and the necessity for further research to optimize treatment protocols.

pharmacology & pharmacy,chemistry, medicinal

[Buccotemporal space and other fascial spaces of the deep lateral face region].

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

Theranostics in Neuroendocrine Tumors

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

Selective neuroinhibitory effects of taurine in slices of rat main olfactory bulb

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management

[Correlation between clinical status and psychological variables in juvenile diabetics (author's transl)].

Peptide receptor radionuclide therapy in patients with advanced pancreatic neuroendocrine tumors

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Ascorbic acid-2-sulfate of the brine shrimp, Artemia salina.

Thalamic Deep Brain Stimulation for Writer's Cramp.

Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource Environment

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review